Cost Curve

A New JAMA Paper Finds Hospitals Aren’t Sharing the Savings from Cancer Biosimilars

Brian Reid

Three 340B Narratives to Watch: State Medicaid vs. 340B Providers, the Impact of 340B on Smaller Clinics, and What’s Next in STD Loophole Litigation

UCB releases its list- and net-price disclosures for 2025, making it the third company to show net prices continue to fall

Brian Reid

CMS Announces Details on Its Plan to Bring Obesity Meds Into Medicare

But the details suggest that the Trump administration may struggle to get the effort off the ground

Brian Reid

GSK’s Price Transparency Data Is Out; Net Prices Are Falling

And Novo will book an extra $4 billion in revenue, citing confidence that its 340B contract pharmacy policies are safe from legal challenges

Brian Reid

Are Medicines on TrumpRx Seeing a Boost in Prescriptions? The Data Suggests the Answer Is (Mostly) ‘No’

And the reality that MFN may mean poor access in Europe, not lower prices in the U.S., begins to sink in

Brian Reid

Lilly Supercharges the ‘Pharm-to-Conference-Table’ Ecosystem, Partnering With 18 Companies to Bring Lower Zepbound Prices to Employers

And a new resource that makes plain the extent -- and variability -- of hospital markups on pharmaceuticals

Brian Reid

Sanofi’s Transparency Report Highlights the Continued Growth of Rebates Paid to Payers

And CMS ‘explanations’ for Medicare drug pricing suggest drugmakers and CMS didn’t see eye-to-eye in half of all ‘negotiations’

Brian Reid

Pharmacists Say the Rollout of ‘Negotiated’ Prices in Medicare Is Leading to a Cash-Flow Crunch

And CMS extends the deadline for its MFN-in-Medicaid program in an effort to get small- and mid-size companies on board

Brian Reid

Four Takeaways from Minnesota’s 340B Transparency Report

And STAT digs into drugmaker annual reports and finds that some MFN deals are not yet finalized

Brian Reid